Clearance of t-PA, PAI-1, and t-PA-PAI-1 complex in an isolated perfused rat liver system
- PMID: 1899689
Clearance of t-PA, PAI-1, and t-PA-PAI-1 complex in an isolated perfused rat liver system
Abstract
The role of physiologic inhibitors of tissue-type plasminogen activator (t-PA) in its clearance has not yet been defined. In this study, the clearance of t-PA, plasminogen activator inhibitor 1 (PAI-1), and t-PA-PAI-1 complex was determined in an isolated perfused rat liver system. The clearance of t-PA-PAI-1 complex was twice as fast as that of t-PA, whereas PAI-1 was cleared slowly. The half-lives for t-PA, determined by a two-compartmental pharmacokinetic model, were: alpha, 20.1 minutes, and beta, 120.0 minutes. The corresponding values for t-PA-PAI-1 complex were: alpha, 9.7 minutes, and beta, about 7 hours. The model microconstants were computed for t-PA and t-PA-PAI-1 complex and the marked difference between the "on" microconstants k12 for t-PA (0.026 +/- 0.001 min-1) and t-PA-PAI-1 complex (0.090 +/- 0.025 min-1) suggests that the effect on binding to liver cells is the most important factor in the faster clearance of t-PA-PAI-1 complex when compared with t-PA.
Similar articles
-
Characterization of the interaction of a complex of tissue-type plasminogen activator and plasminogen activator inhibitor type 1 with rat liver cells.Thromb Haemost. 1995 Nov;74(5):1298-304. Thromb Haemost. 1995. PMID: 8607113
-
A kinetic model of the circulatory regulation of tissue plasminogen activator.Thromb Haemost. 1991 Sep 2;66(3):321-8. Thromb Haemost. 1991. PMID: 1746003
-
Nonlinear pharmacokinetics of tissue-type plasminogen activator in three animal species and isolated perfused rat liver.J Pharmacol Exp Ther. 1990 Oct;255(1):318-24. J Pharmacol Exp Ther. 1990. PMID: 2120422
-
[Tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor (PAI)].Rinsho Byori. 1994 Apr;42(4):346-51. Rinsho Byori. 1994. PMID: 8176842 Review. Japanese.
-
Fibrinolysis in patients with acute ischaemic heart disease. With particular reference to systemic effects of tissue-type plasminogen activator treatment on fibrinolysis, coagulation and complement pathways.Dan Med Bull. 1993 Sep;40(4):383-408. Dan Med Bull. 1993. PMID: 8222763 Review.
Cited by
-
Interaction of mutants of tissue-type plasminogen activator with liver cells: effect of domain deletions.Biochem J. 1996 Feb 1;313 ( Pt 3)(Pt 3):775-80. doi: 10.1042/bj3130775. Biochem J. 1996. PMID: 8611154 Free PMC article.
-
Plasminogen Activator Inhibitor-1 and Oncogenesis in the Liver Disease.J Cell Signal. 2021;2(3):221-227. doi: 10.33696/signaling.2.054. J Cell Signal. 2021. PMID: 34671766 Free PMC article.
-
Characterization of the binding of plasminogen activators to plasma membranes from human liver.Biochem J. 1992 Nov 1;287 ( Pt 3)(Pt 3):911-5. doi: 10.1042/bj2870911. Biochem J. 1992. PMID: 1445249 Free PMC article.
-
Tissue plasminogen activator, plasminogen activator inhibitors, and activator-inhibitor complex in liver disease.J Clin Pathol. 1994 Mar;47(3):214-7. doi: 10.1136/jcp.47.3.214. J Clin Pathol. 1994. PMID: 8163691 Free PMC article.
-
Metformin, but not glimepiride, improves carotid artery diameter and blood flow in patients with type 2 diabetes mellitus.Clinics (Sao Paulo). 2012 Jul;67(7):711-7. doi: 10.6061/clinics/2012(07)03. Clinics (Sao Paulo). 2012. PMID: 22892913 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Miscellaneous